Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|May 18, 2023
Isolation and Cryopreservation of Mononuclear Cells from Peripheral Blood and Bone Marrow of Blood Cancer PatientsSarah Brophy, Rebecca Amet, Hayley Foy-Stones, et al.
Case Reports in Hematology|May 9, 2013
BRAF V600E-Negative Hairy Cell LeukaemiaStephen E Langabeer, David O'Brien, Anthony M McElligott, et al.
Pharmaceuticals (Basel, Switzerland)|December 29, 2020
Exploring the Anti-Cancer Mechanism of Novel 3,4'-Substituted Diaryl Guanidinium DerivativesViola Previtali, Helene B Mihigo, Rebecca Amet, et al.
Leukemia Research|January 11, 2012
Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemiaStephen E Langabeer, Fiona Quinn, David O'Brien, et al.
Clinical Immunology (Orlando, Fla.)|August 7, 2017
Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8+ invariant natural killer T cellsYasmeen G Ghnewa, Vincent P O'Reilly, Elisabeth Vandenberghe, et al.
International Journal of Oncology|November 9, 2012
The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cellsJoanne Lysaght, Navin K Verma, Elaina N Maginn, et al.
Cancer Biology & Therapy|December 7, 2010
Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitroJames C Forde, Elaina N Maginn, Gillian McNamara, et al.
Journal of Molecular Medicine (Berlin, Germany)|February 14, 2008
A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulinNavin K Verma, Eugene Dempsey, Jennifer Conroy, et al.
Molecules (Basel, Switzerland)|December 23, 2023
Synthesis and Pro-Apoptotic Effects of Nitrovinylanthracenes and Related Compounds in Chronic Lymphocytic Leukaemia (CLL) and Burkitt's Lymphoma (BL)Andrew J Byrne, Sandra A Bright, James P McKeown, et al.
Life Sciences|December 26, 2021
A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myelomaRebecca Amet, Viola Previtali, Helene B Mihigo, et al.
Pageof 2